There's bad news on the clinical trial front.
News & Analysis: NewLink Genetics
New data on NewLink's lead drug puts some pep in this clinical-stage drug developers' step.
An anticipated secondary offering appears to be priced better than expected.
Why small-cap biotechs Celldex Therapeutics, Idera Pharmaceuticals, and NewLink Genetics could be big winners.
Insmed, Newlink Genetics, and Voyager Therapeutics stocks soar on positive news.
On a day when the broader market held relatively steady amid conflicting currents, these stocks rose. Find out why.
Analysts weigh in with positive comments following updated mid-stage trial results for its IDO inhibitor.
Updated mid-stage trial results for its IDO-inhibitor are sparking investor optimism.
Disappointing trials from XBiotech, Merrimack Pharmaceuticals, and NewLink Genetics have earned the market's ire. But are their declines overdone?
Roche Holdings has decided to walk away from co-developing NewLink Genetics IDO-inhibitor, GDC-0919.